GW Pharmaceuticals (NASDAQ:GWPH) Issues Quarterly Earnings Results


Share on StockTwits

GW Pharmaceuticals (NASDAQ:GWPH) released its earnings results on Sunday. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.31, Fidelity Earnings reports. GW Pharmaceuticals had a negative return on equity of 7.46% and a negative net margin of 11.05%.

NASDAQ:GWPH traded down $0.32 during trading hours on Tuesday, hitting $218.96. 1,459,734 shares of the stock traded hands, compared to its average volume of 899,737. The company has a quick ratio of 4.31, a current ratio of 5.13 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals has a 1 year low of $87.07 and a 1 year high of $219.57. The company has a market cap of $6.86 billion, a price-to-earnings ratio of -127.30 and a beta of 2.15. The stock has a 50 day moving average price of $217.57 and a 200 day moving average price of $163.58.

In other news, Director Cabot Brown sold 4,020 shares of GW Pharmaceuticals stock in a transaction that occurred on Thursday, March 18th. The shares were sold at an average price of $17.95, for a total transaction of $72,159.00. Following the sale, the director now owns 7,200 shares in the company, valued at $129,240. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Volker Knappertz sold 3,060 shares of GW Pharmaceuticals stock in a transaction that occurred on Friday, March 26th. The shares were sold at an average price of $18.10, for a total transaction of $55,386.00. Following the sale, the director now owns 92,412 shares in the company, valued at approximately $1,672,657.20. The disclosure for this sale can be found here. Insiders have sold 15,480 shares of company stock worth $279,753 in the last ninety days. Insiders own 3.10% of the company’s stock.

Several research analysts have recently weighed in on the company. Cantor Fitzgerald cut GW Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Wednesday, February 3rd. Zacks Investment Research upgraded GW Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 27th. SVB Leerink cut GW Pharmaceuticals from an “outperform” rating to a “market perform” rating and boosted their price target for the stock from $200.00 to $220.00 in a research note on Thursday, February 4th. Needham & Company LLC restated a “hold” rating on shares of GW Pharmaceuticals in a research note on Wednesday, February 3rd. Finally, Citigroup cut GW Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Thursday, February 4th. Eleven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $197.75.

About GW Pharmaceuticals

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.

Further Reading: Earnings Per Share

Earnings History for GW Pharmaceuticals (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.